Platelet aggregate formation in vivo was assessed by means of the platelet aggregate ratio and from platelet release products (I thromboglobulin, platelet factor 4, thromboxane B2) in 23 patients with chronic airflow obstruction with and without hypoxaemia and in 10 control subjects without respiratory disease. Eight of the 11 hypoxaemic patients were having long term oxygen therapy. The platelet aggregate ratio was lower in the hypoxaemic patients (0-88 (SE 0-03)) than in the non-hypoxaemic (0 97 (0-01)) and control groups (1O00 (0 02)), and there was a trend to lower aggregate ratios in the more hypoxaemic patients. Platelet release products in the peripheral venous blood were not increased in the patients or control subjects. Platelet behaviour is altered in chronic hypoxaemia and this enhanced platelet activity could contribute to the pulmonary vascular damage found in these patients through direct effects or mediator release. We have investigated platelet function further in patients with chronic airflow obstruction with and without hypoxaemia, measuring platelet aggregate formation in vivo in addition to blood concentrations of various platelet release products.
Various factors are known to contribute to pulmonary hypertension in patients with chronic hypoxaemic lung disease, including hypoxaemia, structural changes in the pulmonary arterioles, polycythaemia, an increased blood volume, and mechanical factors (by an increase in airway resistance and thus mean alveolar pressure).' Platelets play an important part in thrombosis and vascular damage, but their role in the development of pulmonary vascular changes in patients with chronic hypoxaemia is uncertain.
We have previously shown that platelets from patients with chronic hypoxaemia are larger, with a greater mean volume.2 These larger platelets are haemostatically more active and show an increased tendency to aggregate; platelet aggregation could have contributed to the apparent increase in platelet volume.34 Chronic hypoxaemia is associated with a decrease in platelet survival time, suggesting increased platelet consumption. 5 Platelet aggregation, when assessed by in vitro methods, is increased in patients with chronic hypoxaemia and chronic airflow obstruction. 6 We have investigated platelet function further in patients with chronic airflow obstruction with and without hypoxaemia, measuring platelet aggregate formation in vivo in addition to blood concentrations of various platelet release products.
Methods
We studied 23 patients with chronic airflow obstruction and a wide range of arterial blood gas tensions. Eleven of the patients (mean (SD) age 66 (6 5) years) were hypoxaemic (arterial oxygen tension (Pao2) 8 kPa or less) and 12 patients (mean age 62 (6&6) years) had no hypoxaemia. Eight of the hypoxaemic group were having long term oxygen therapy, with standard instructions to use oxygen for 15 hours daily. All the patients were stable clinically with no exacerbations of their airflow obstruction for two weeks before the study. None of the patients was taking any medication known to affect platelet function. Ten control subjects from the same age range (mean age 60 (7-1) years) with no evidence of respiratory disease were also recruited. The study was approved by the ethics committees of the Royal Brompton National Heart and Lung Hospitals and the London Hospital.
Sampling for the platelet studies was performed under standardised conditions; no coffee, tea or theophylline was taken on the day of the study. The patients and control subjects attended the laboratory in the morning and rested for at least an hour. Blood was then sampled by direct venepuncture with a vacutainer, without the use of a tourniquet, from a large vein in the antecubital fossa.
The platelet aggregate ratio, a quantitative measure ofplatelet aggregate formation in vivo, was measured by a method modified from that described by Wu and Hoak7: 1-5 ml of blood was taken into a vacutainer filled with 3 5 ml of 4-5 mM Na2 HPO4, 1-6 mM KH2 P04, and 5-8 mM tripotassium EDTA in normal saline containing 0-15% formaldehyde. A further 1-5 ml of the blood sample was taken into a similar tube without the addition of formaldehyde. Any aggregates formed as a result of exposure of susceptible platelets to a particular microenvironment are fixed in the formalin-EDTA mixture but broken up by the high concentration of EDTA in the "EDTA alone" mixture. The platelet aggregate ratio is given by the ratio of the platelet count in the formalin-EDTA mixture to that in the EDTA mixture, the count having been corrected for packed cell volume. In the absence of platelet aggregates the platelet aggregate ratio approaches l 0.
Three millilitres of blood were taken into EDTA for a routine haematology profile, a Pao,-arterial oxygen tension; Paco2-arterial carbon dioxide tension; FEV1-forced expiratory volume in one second; FVC-forced vital capacity.
Coulter counter being used (model S Plus IV) Plasma fibrinogen concentrations were measured by the method of Clauss. The hypoxaemic patients had a lower Pao2 (p < 0-001) and a higher arterial carbon dioxide tension (Paco2) (p < 0-001) than the nonf hypoxaemic group. All the non-hypoxaemic patients and control subjects were non-smokers and had carboxyhaemoglobin concentrations within the normal range (under 3%). In the hypoxaemic group four patients had carboxyhaemoglobin concentrations in the range seen in smokers (3-2%-7-8%), though only three were declared smokers. There was no significant difference in the forced expiratory volume in one second (FEVI) or forced vital capacity (FVC) between the two groups of patients, but the hypoxaemic patients had a higher packed cell volume (p < 0-001). The platelet aggregate ratios for the three groups are shown in figure 1. The ratio was lower in the hypoxaemic group (mean (SE) ratio 0-88 (0-03)) than in the non-hypoxaemic group (0-97 (0-01)) or the control subjects (1-0 (0-02)). The mean difference (95% confidence limits) between the hypoxaemic and the nonhypoxaemic patients was -0-09 (-0-15, -0-03) and between the hypoxaemic and the control subjects -0-12 (-0-19, -0-05). There was a trend for patients with lower platelet aggregate ratios to have lower Pao2 values ( fig 2) and higher Paco2 values. Within the hypoxaemic group there was no difference in mean platelet aggregate ratio between the four patients who had a carboxyhaemoglobin concentration greater than 30/0 (mean ratio 0-89 (SE 0-06)) and the seven patients with a blood carboxyhaemoglobin level below 3% (mean ratio 0-87 (SE 0-03)), the mean difference being 0-02 (95% CL -0-02, 0-06). increase in platelet factor 4 in the hypoxaemic group, this was not significant. No differences were observed in thromboxane B2 concentrations or in platelet counts. Blood fibrinogen concentrations were slightly higher in the hypoxaemic group but not significantly so.
Discussion
In this study the platelet aggregate ratio was lower in patients with chronic airflow obstruction and hypoxaemia than in patients without arterial hypoxaemia or in control subjects without respiratory disease. We found no effect of blood carboxyhaemoglobin concentration on platelet aggregate formation, though the number of smokers in the study was small. Cigarette smoking is associated with enhanced platelet activity9 and further studies are required to assess the effect of smoking on platelet function in hypoxaemic patients. Eight of the 1 1 hypoxaemic patients in this study were having long term oxygen therapy at home. As oxygen therapy can improve platelet survival in patients with chronic hypoxaemia,5 possibly oxygen therapy also reduced some of the changes in platelet aggregate ratios or release products in our patients. The reduction in the platelet aggregate ratio suggests that patients with chronic hypoxaemia have more active platelets with an increased (ng/mi, GM (95% CL)) (24-9, 61 9) (227, 45-8) (16 9, 53-5) Platelet factor 4 (ng/ml) 15 because of the small -numbers in the study, there is not enough power to detect differences that may truly exist. This study shows that platelet behaviour is altered in patients with chronic hypoxaemia. These active platelets may, through direct effects or mediator release, cause local pulmonary vascular damage and lead to the development of pulmonary hypertension. Modulation of platelet activity by oxygen or pharmacological methods might reduce pulmonary hypertension, but this needs to be determined. 
